First- and second-line treatments for locally advanced renal cell carcinoma | EXEL Message Board Posts


  • Get 3 months of ad-free premium service for every $25 you contribute
    to support critical site improvement efforts.
    With no recurring subscription
    to worry about, this an ideal way to test drive our premium service.

    Premium features, such as multi-message viewing (i.e., being able to open
    up to 100 messages with a single click) can save you lots of time
    over the course of a busy day, to say nothing of an entire year!
    Watch this 2-min video to see why premium is right for you.


    *Offer expires at midnight

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22224 of 22941  at  6/18/2019 9:57:10 PM  by

Pacific


First- and second-line treatments for locally advanced renal cell carcinoma

https://www.youtube.com/watch?v=Ob5o7wPKua0

Published on Jun 18, 2019

Prof Jorge Garcia speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the various treatment options available for locally advanced renal cell carcinoma (RCC) patients in both the first-line and second-line setting.

Prof Garcia describes the historic use of targeted therapies such as tyrosine kinase and vascular endothelial growth factor inhibitors as the standard front-line choice of therapy for these patients.

For the second-line setting, he also states two agents (cabozantinib and nivolumab) which have both demonstrated a survival benefit for advanced RCC patients.

Over the last 18 months, Prof Garcia notes the utilisation of immuno-oncology agents in patients with untreated RCC during the front-line setting. In particular the use of the ipilimumab plus nivolumab regimen, which has become the standard of care in men with untreated, clear cell, metastatic RCC. However, this may change with encouraging data supporting the use of the pembrolizumab/axitinib regimen.

Prof Garcia concludes by stating the challenges clinicians face in the treatment of RCC, which include the absence of an effective biomarker which leads to the reliance of obsolete clinical features.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 251
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
22229 Re: First- and second-line treatments for locally advanced renal cell carcinoma commonwealthinc 2 6/19/2019 9:46:17 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...